Lazar Mandinov
Corporate Officer/Principal chez The European Society of Cardiology
Profil
Lazar Mandinov is a member of The European Society of Cardiology.
He previously worked as a Medical Director at Boston Scientific Corp., Chief Medical Officer at Mitralign, Inc., and Principal at Maine Medical Center Research.
Dr. Mandinov holds a doctorate degree from Medical University Sofia.
Postes actifs de Lazar Mandinov
| Sociétés | Poste | Début |
|---|---|---|
| The European Society of Cardiology | Corporate Officer/Principal | - |
Anciens postes connus de Lazar Mandinov
| Sociétés | Poste | Fin |
|---|---|---|
| BOSTON SCIENTIFIC CORPORATION | Directeur Technique/Scientifique/R&D | - |
| Maine Medical Center Research | Corporate Officer/Principal | - |
Mitralign, Inc.
 Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Directeur Technique/Scientifique/R&D | - |
Formation de Lazar Mandinov
| Medical University Sofia | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BOSTON SCIENTIFIC CORPORATION | Health Technology |
| Entreprise privées | 3 |
|---|---|
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Health Technology |
| The European Society of Cardiology | |
| Maine Medical Center Research |
